[go: up one dir, main page]

WO2009150284A3 - Conjugados de apo-a para la administración de compuestos biológicamente activos - Google Patents

Conjugados de apo-a para la administración de compuestos biológicamente activos Download PDF

Info

Publication number
WO2009150284A3
WO2009150284A3 PCT/ES2009/070224 ES2009070224W WO2009150284A3 WO 2009150284 A3 WO2009150284 A3 WO 2009150284A3 ES 2009070224 W ES2009070224 W ES 2009070224W WO 2009150284 A3 WO2009150284 A3 WO 2009150284A3
Authority
WO
WIPO (PCT)
Prior art keywords
apo
conjugates
administration
biologically active
active compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES2009/070224
Other languages
English (en)
French (fr)
Other versions
WO2009150284A9 (es
WO2009150284A2 (es
Inventor
Jesús María PRIETO VALTUEÑA
Pedro BERRAONDO LÓPEZ
Jessica Fioravanti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proyecto de Biomedicina CIMA SL
Original Assignee
Proyecto de Biomedicina CIMA SL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to MX2010013759A priority Critical patent/MX2010013759A/es
Priority to BRPI0915093A priority patent/BRPI0915093A2/pt
Priority to US12/997,829 priority patent/US20110293557A1/en
Priority to CN200980131382.9A priority patent/CN102123737B/zh
Priority to RU2011100801/10A priority patent/RU2567667C2/ru
Priority to JP2011513010A priority patent/JP5685529B2/ja
Priority to AU2009256547A priority patent/AU2009256547B2/en
Priority to CA2727811A priority patent/CA2727811A1/en
Application filed by Proyecto de Biomedicina CIMA SL filed Critical Proyecto de Biomedicina CIMA SL
Priority to EP09761841A priority patent/EP2305309A2/en
Publication of WO2009150284A2 publication Critical patent/WO2009150284A2/es
Publication of WO2009150284A3 publication Critical patent/WO2009150284A3/es
Anticipated expiration legal-status Critical
Publication of WO2009150284A9 publication Critical patent/WO2009150284A9/es
Priority to US14/947,164 priority patent/US20160074475A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/775—Apolipopeptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Psychology (AREA)

Abstract

La invención se relaciona con un conjugado que comprende una molécula de Apo A o una variante funcionalmente equivalente de la misma y un compuesto de interés terapéutico en donde ambos componentes se encuentran unidos covalentemente así como a los usos de dichos conjugados en terapia para el direccionamiento específico de dichos compuestos a aquellos tejidos que presentas sitios de unión específicos para la molécula de ApoA.
PCT/ES2009/070224 2008-06-13 2009-06-12 Conjugados de apo-a para la administración de compuestos biológicamente activos Ceased WO2009150284A2 (es)

Priority Applications (10)

Application Number Priority Date Filing Date Title
AU2009256547A AU2009256547B2 (en) 2008-06-13 2009-06-12 Apo-A conjugates for the administration of biologically active compounds
US12/997,829 US20110293557A1 (en) 2008-06-13 2009-06-12 Conjugates for the administration of biologically active compounds
CN200980131382.9A CN102123737B (zh) 2008-06-13 2009-06-12 用于生物活性化合物施用的轭合物
RU2011100801/10A RU2567667C2 (ru) 2008-06-13 2009-06-12 Конъюгаты для введения биологически активных соединений
JP2011513010A JP5685529B2 (ja) 2008-06-13 2009-06-12 生物学的活性を有する化合物の投与のための複合体
CA2727811A CA2727811A1 (en) 2008-06-13 2009-06-12 Conjugates for the administration of biologically active compounds
EP09761841A EP2305309A2 (en) 2008-06-13 2009-06-12 Conjugates for the administration of biologically active compounds
MX2010013759A MX2010013759A (es) 2008-06-13 2009-06-12 Conjugados para la administracion de compuestos biologicamente activos.
BRPI0915093A BRPI0915093A2 (pt) 2008-06-13 2009-06-12 conjugados para a administração de compostos biologicamente ativos
US14/947,164 US20160074475A1 (en) 2008-06-13 2015-11-20 Conjugates for the administration of biologically active compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP200801796 2008-06-13
ES200801796 2008-06-13

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/997,829 A-371-Of-International US20110293557A1 (en) 2008-06-13 2009-06-12 Conjugates for the administration of biologically active compounds
US14/947,164 Division US20160074475A1 (en) 2008-06-13 2015-11-20 Conjugates for the administration of biologically active compounds

Publications (3)

Publication Number Publication Date
WO2009150284A2 WO2009150284A2 (es) 2009-12-17
WO2009150284A3 true WO2009150284A3 (es) 2010-12-09
WO2009150284A9 WO2009150284A9 (es) 2011-02-03

Family

ID=41338617

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES2009/070224 Ceased WO2009150284A2 (es) 2008-06-13 2009-06-12 Conjugados de apo-a para la administración de compuestos biológicamente activos

Country Status (10)

Country Link
US (2) US20110293557A1 (es)
EP (1) EP2305309A2 (es)
JP (2) JP5685529B2 (es)
CN (1) CN102123737B (es)
AU (1) AU2009256547B2 (es)
BR (1) BRPI0915093A2 (es)
CA (1) CA2727811A1 (es)
MX (1) MX2010013759A (es)
RU (1) RU2567667C2 (es)
WO (1) WO2009150284A2 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2347627B1 (es) * 2009-03-06 2011-10-10 Isdin, S.A. Peptido para el tratamiento profilactico o terapeutico de tumores de la piel en estadios iniciales.
CA2783876C (en) 2009-12-11 2018-04-03 Proyecto De Biomedicina Cima, S.L. New conjugates and compositions for immunotherapy and antitumoral treatment
US20120308517A1 (en) 2010-02-09 2012-12-06 Digna Biotech, S.L. Compositions for the treatment of infectious and tumoural diseases
WO2011159771A2 (en) * 2010-06-15 2011-12-22 The Cleveland Clinic Foundation Compositions and methods for treating cancer
HUE042314T2 (hu) 2011-02-07 2019-06-28 Cerenis Therapeutics Holding Sa Lipoprotein komplexek és azok gyártása és alkalmazásai
JP2014132832A (ja) * 2011-05-10 2014-07-24 Sekisui Chem Co Ltd 医薬、機能性食品、目的蛋白質の安定化方法、融合蛋白質、核酸、並びに、組換え体
BR112013033562A2 (pt) * 2011-08-25 2017-02-14 Hoffmann La Roche proteína de fusão de tetranectina-apolipoproteína a-i encurtada, uma partícula de lipídio que a contém e uso das mesmas
CN103073646A (zh) * 2012-03-13 2013-05-01 华中科技大学 一种运载蜂毒肽的多肽、运载蜂毒肽的纳米颗粒及其应用
ES2427854B1 (es) * 2012-03-29 2014-09-15 Universidad De Valladolid Sensores de calcio y métodos para la detección de calcio libre intracelular
EP2735874A1 (en) 2012-11-21 2014-05-28 Fundación Para La Investigación Biomédica Del Hospital Universitario Puerta De Hierro Methods of diagnosing and therapeutic agents for use in the treatment of prostate cancer
CA3190893A1 (en) * 2013-06-05 2014-12-11 Csl Limited Process for preparing apolipoprotien a-i (apo a-i)
KR101656929B1 (ko) * 2014-06-02 2016-09-13 씨제이제일제당 (주) 반추동물의 메탄 생성 저감용 사료 첨가제 조성물
GB201410507D0 (en) * 2014-06-12 2014-07-30 Univ Bath Drug delivery enhancement agents
KR102440820B1 (ko) * 2015-09-08 2022-09-05 테리피온, 인크. ApoA-1 융합 폴리펩티드 및 관련 조성물 및 방법
US11390854B2 (en) 2017-05-09 2022-07-19 Fundacion Para La Investigacion Medica Aplicada Human porphobilinogen deaminase derived proteins and polynucleotides and uses thereof
CN110483648A (zh) * 2019-08-27 2019-11-22 南京安吉生物科技有限公司 一种融合多肽及其应用
FR3100715B1 (fr) * 2019-09-12 2023-09-29 Francais Du Sang Ets Utilisation de HDL dans la prophylaxie de la maladie du greffon contre l’hôte

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
WO2004041179A2 (en) * 2002-10-30 2004-05-21 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Scavenger receptor b1 (cla-1) targeting for the treatment of infection, sepsis and inflammation
WO2005070400A1 (en) * 2004-01-15 2005-08-04 Mount Sinai School Of Medicine Methods and compositions for imaging
US20060252694A1 (en) * 1997-09-29 2006-11-09 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
WO2008007146A1 (en) * 2006-07-13 2008-01-17 Upperton Limited Process for preparing particles of proteinaceous material
US20080138394A1 (en) * 2006-11-09 2008-06-12 Mogam Biotechnology Research Institute Composite For Liver-Specific Delivery and Release of Therapeutic Nucleic Acids or Drugs
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2009036460A2 (en) * 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0239631A4 (en) 1985-10-04 1989-01-12 Biotech Res Partners Ltd RECOMBINANT APOLIPOPROTEINS AND METHODS.
US5643757A (en) 1994-03-21 1997-07-01 American Cyanamid Company High yield production of human apolipoprotein A1 in E. coli.
US5766582A (en) 1994-10-11 1998-06-16 Schering Corporation Stable, aqueous alfa interferon solution formulations
JP2758154B2 (ja) 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
CA2274241C (en) 1996-08-23 2003-05-27 Esperion Therapeutics Inc. A process for purifying apolipoprotein a or apolipoprotein e from human plasma
EP0942935A1 (en) 1996-09-11 1999-09-22 Pharmacia & Upjohn Aktiebolag A process for purifying apolipoproteins and a composition for use in the process
ES2146552B1 (es) 1998-11-24 2001-04-16 Inst Cientifico Tecnol Navarra Peptidos inhibidores de tgf/31
US6809186B1 (en) 1999-01-22 2004-10-26 Martek Biosciences Corporation Simple method for labeled conjugate production
AU2001253620A1 (en) * 2000-04-14 2001-10-30 Nuvelo, Inc. Materials and methods relating to lipid metabolism
AU2008201887B2 (en) * 2000-11-10 2011-06-30 F. Hoffmann-La Roche Ltd. Apolipoprotein analogues
CN1520259A (zh) 2001-04-25 2004-08-11 ���ݴ�ѧУ��ίԱ�� 利用球状载体将第八因子/第九因子进行肝脏基因转移治疗血友病的方法
US8877901B2 (en) 2002-12-13 2014-11-04 Immunomedics, Inc. Camptothecin-binding moiety conjugates
EP1572242B1 (en) 2002-12-13 2014-04-16 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
TW201424770A (zh) * 2003-02-14 2014-07-01 Childrens Hosp & Res Ct Oak 親脂藥物傳送媒介物及其使用方法
JP2004277355A (ja) 2003-03-17 2004-10-07 Beacle Inc 血友病治療用薬剤及びそれを用いた血友病治療方法
ES2304069B1 (es) 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US7431915B2 (en) * 2003-10-31 2008-10-07 The Regents Of The University Of California Peptides whose uptake by cells is controllable
WO2005051315A2 (en) 2003-11-24 2005-06-09 The Regents Of The University Of California On-demand cleavable linkers for radioconjugates for cancer imaging and therapy
ES2344302T3 (es) * 2004-02-10 2010-08-24 Zystor Therapeutics , Inc. Alfa glucosidasa acida y fragmentos de la misma.
US20060051859A1 (en) * 2004-09-09 2006-03-09 Yan Fu Long acting human interferon analogs
WO2006135436A2 (en) 2004-10-22 2006-12-21 University Of Florida Research Foundation, Inc. Inhibition of gene expression and therapeutic uses thereof
CN101484182B (zh) 2005-04-06 2014-06-11 Ibc药品公司 由同二聚体、同四聚体或二聚体的二聚体组成的稳定连接复合体的生产方法及用途
KR20080071119A (ko) 2005-08-12 2008-08-01 휴먼 게놈 사이언시즈, 인코포레이티드 알부민 융합 단백질
WO2007023476A2 (en) 2005-08-26 2007-03-01 Cerenis Therapeutics Holding Sa Compositions and methods for producing apolipoprotein gene products in lactic acid bacteria
JP5231231B2 (ja) 2005-10-19 2013-07-10 アイビーシー・ファーマシューティカルズ・インコーポレーテッド 複雑性が増大した生理活性アセンブリーを生成するための方法および組成物ならびに使用
CN101340927A (zh) 2005-10-24 2009-01-07 西玛生物医学信息公司 TGF-β1抑制性多肽在制备免疫反应调节剂上的用途
EP1969000A2 (en) 2005-12-06 2008-09-17 Centre National de la Recherche Scientifique Cell penetrating peptides for intracellular delivery of molecules
US20090238883A1 (en) 2006-04-28 2009-09-24 Kren Betsy T Liver-specific nanocapsules and methods of using

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987002061A1 (en) * 1985-10-03 1987-04-09 Biotechnology Research Partners, Ltd. Novel lipoprotein-based drug-delivery systems
US20060252694A1 (en) * 1997-09-29 2006-11-09 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
WO2004041179A2 (en) * 2002-10-30 2004-05-21 The United States Of America As Represented By The Secretary Of Health And Human Services, Nih Scavenger receptor b1 (cla-1) targeting for the treatment of infection, sepsis and inflammation
WO2005070400A1 (en) * 2004-01-15 2005-08-04 Mount Sinai School Of Medicine Methods and compositions for imaging
US20080206142A1 (en) * 2006-06-16 2008-08-28 Lipid Sciences, Inc. Novel Peptides That Promote Lipid Efflux
WO2008007146A1 (en) * 2006-07-13 2008-01-17 Upperton Limited Process for preparing particles of proteinaceous material
US20080138394A1 (en) * 2006-11-09 2008-06-12 Mogam Biotechnology Research Institute Composite For Liver-Specific Delivery and Release of Therapeutic Nucleic Acids or Drugs
US20090110739A1 (en) * 2007-05-15 2009-04-30 University Of North Texas Health Science Center At Forth Worth Targeted cancer chemotherapy using synthetic nanoparticles
WO2009036460A2 (en) * 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AKHURST R J: "Large- and small-molecule inhibitors of transforming growth factor-[beta] signaling", CURRENT OPINION IN INVESTIGATIONAL DRUGS, vol. 7, no. 6, June 2006 (2006-06-01), pages 513 - 521, XP008127792, ISSN: 1472-4472 *
CORBIN I R ET AL: "Enhanced cancer-targeted delivery using engineered high-density lipoprotein-based nanocarriers", JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, vol. 3, no. 4, December 2007 (2007-12-01), pages 367 - 376, XP007914544, DOI: 10.1166/JBN.2007.053 *
D'ARONDEL C ET AL: "A prospective assessment of an 'a la carte' regimen of PEG-interferon alpha2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers", JOURNAL OF VIRAL HEPATITIS, vol. 13, no. 3, March 2006 (2006-03-01), pages 182 - 189, XP002597776, DOI: 10.1111/J.1365-2893.2005.00668.X *
DOTOR ET AL: "Identification of peptide inhibitors of transforming growth factor beta 1 using a phage-displayed peptide library", CYTOKINE, ACADEMIC PRESS LTD, PHILADELPHIA, PA, US LNKD- DOI:10.1016/J.CYTO.2007.06.004, vol. 39, no. 2, 6 October 2007 (2007-10-06), pages 106 - 115, XP022289351, ISSN: 1043-4666 *
GLASS C K ET AL: "TISSUE SITES OF DEGRADATION OF APO PROTEIN A-I IN THE RAT", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 258, no. 11, 1983, pages 7161 - 7167, XP002597775, ISSN: 0021-9258 *
KREUTER ET AL: "Covalent attachment of apolipoprotein A-I and apolipoprotein B-100 to albumin nanoparticles enables drug transport into the brain", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.JCONREL.2006.12.012, vol. 118, no. 1, 24 February 2007 (2007-02-24), pages 54 - 58, XP005903632, ISSN: 0168-3659 *
KREUTER J ET AL: "APOLIPOPROTEIN-MEDIATED TRANSPORT OF NANOPARTICLE-BOUND DRUGS ACROSS THE BLOOD-BRAIN BARRIER", JOURNAL OF DRUG TARGETING, HARWOOD ACADEMIC PUBLISHERS GMBH, DE LNKD- DOI:10.1080/10611860290031877, vol. 10, no. 4, 1 June 2002 (2002-06-01), pages 317 - 325, XP009027368, ISSN: 1061-186X *
MALLAT, ZIAD ET AL: "Inhibition of transforming growth factor-.beta. signaling accelerates atherosclerosis and induces an unstable plaque phenotype in mice", CIRCULATION RESEARCH, vol. 89, no. 10, 2001, pages 930 - 934, XP002604588, ISSN: 0009-7330, DOI: 10.1161/hh2201.099415 *
MORRONE G ET AL: "EFFECT OF TGF-BETA ON LIVER GENES EXPRESSION ANTAGONISTIC EFFECT OF TGF-BETA ON IL-6-STIMULATED GENES IN HEP 3B CELLS", FEBS LETTERS, vol. 301, no. 1, 1992, pages 1 - 4, XP002604585, ISSN: 0014-5793 *
SANTIAGO BEGONA ET AL: "Topical application of a peptide inhibitor of transforming growth factor-beta 1 ameliorates bleomycin-induced skin fibrosis", JOURNAL OF INVESTIGATIVE DERMATOLOGY, vol. 125, no. 3, September 2005 (2005-09-01), pages 450 - 455, XP002604583, ISSN: 0022-202X *
SATO Y. ET AL.: "Lipoprotein(a) induces cell growth in rat peritoneal macrophages through inhibition of transforming growth factor-.beta. activation", ATHEROSCLEROSIS, vol. 125, no. 1, 1996, pages 15 - 26, XP002604584, ISSN: 0021-9150 *
SEOANE J: "The TGF[beta] pathway as a therapeutic target in cancer", CLINICAL AND TRANSLATIONAL ONCOLOGY, vol. 10, no. 1, 2 February 2008 (2008-02-02), pages 14 - 19, XP002604586, ISSN: 1699-048X, DOI: 10.1007/S12094-008-0148-2 *
SKIBA P J ET AL: "Interferon-[gamma] down-regulates the lipoprotein(a)/apoprotein(a) receptor activity on macrophage foam cells. Evidence for disruption of ligand-induced receptor recycling by interferon-[gamma]", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 269, no. 37, 1994, pages 23059 - 23067, XP002597774, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP2305309A2 (en) 2011-04-06
WO2009150284A9 (es) 2011-02-03
JP2011523857A (ja) 2011-08-25
MX2010013759A (es) 2011-05-25
AU2009256547A1 (en) 2009-12-17
JP5685529B2 (ja) 2015-03-18
RU2011100801A (ru) 2012-07-20
WO2009150284A2 (es) 2009-12-17
US20110293557A1 (en) 2011-12-01
JP2015038124A (ja) 2015-02-26
AU2009256547B2 (en) 2014-07-10
CA2727811A1 (en) 2009-12-17
CN102123737A (zh) 2011-07-13
US20160074475A1 (en) 2016-03-17
BRPI0915093A2 (pt) 2015-10-27
RU2567667C2 (ru) 2015-11-10
CN102123737B (zh) 2014-01-01

Similar Documents

Publication Publication Date Title
WO2009150284A3 (es) Conjugados de apo-a para la administración de compuestos biológicamente activos
WO2009126920A3 (en) Human serum albumin linkers and conjugates thereof
WO2006124737A3 (en) Molecular constructs suitable for targeted conjugates
WO2008073162A3 (en) Lysine acetylation sites
WO2010115629A3 (en) Amatoxin-armed therapeutic cell surface binding components designed for tumour therapy
WO2008082613A3 (en) Factor ix moiety-polymer conjugates having a releasable linkage
EP4279140A3 (en) Human antibodies against tissue factor
WO2007106120A3 (en) Serum albumin binding peptides for tumor targeting
WO2008053360A3 (en) Albumin binding molecules and uses thereof
WO2006108405A3 (de) Nanopartikel-wirkstoff-konjugate
UA103758C2 (ru) Конъюгаты олигомеров инсулина, их композиции и применение
WO2006042146A3 (en) Multifunctional nanoparticles conjugates and their use
WO2006079120A3 (en) Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
WO2008017381A8 (de) Arylaminoaryl-alkyl-substituierte imidazolidin-2,4-dione, verfahren zu ihrer herstellung, diese verbindungen enthaltende arzneimittel und ihre verwendung
WO2009071850A8 (fr) Nanoparticules d'actifs therapeutiques de faible solubilite aqueuse
WO2009016516A3 (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
WO2007059404A3 (en) Duocarmycin derivatives as novel cytotoxic compounds and conjugates
WO2005079391A3 (en) Contrast agents for myocardial perfusion imaging
WO2007064345A3 (en) Heterocyclic-substituted bis-1,8 naphthalimide compounds, antibody drug conjugates, and methods of use
EP2292248A3 (en) Anti-angiogenic compounds
WO2008076333A3 (en) Polymer-drug conjugates with tether groups for controlled drug delivery
WO2007062610A3 (es) Dendrímero con peg de cuatro ramas para la conjugación a proteínas y péptidos
WO2010065950A3 (en) Albumin binding peptide-mediated disease targeting
EP1983002A3 (en) Tyrosine phosphorylation sites and antibodies specific for them
WO2006095234A3 (en) Integrin targeted synthetic ligands for diagnostic and therapeutic applications

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200980131382.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09761841

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011513010

Country of ref document: JP

Ref document number: 12997829

Country of ref document: US

Ref document number: 2727811

Country of ref document: CA

Ref document number: MX/A/2010/013759

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 4868/KOLNP/2010

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2009761841

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2011100801

Country of ref document: RU

ENP Entry into the national phase

Ref document number: 2009256547

Country of ref document: AU

Date of ref document: 20090612

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0915093

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20101213